Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

InfuSystem Holdings, Inc

NYSE: INFU · Industrial Applications and Services · 4 alerts · CIK 1337013

Share price
$14.79Close, Nov 16
Market cap
$296M
Shares outstanding
20.03MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All InfuSystem Holdings, Inc filings on SEC EDGAR ↗

4:34 PM ET 10-Q
Financial Results

InfuSystem Holdings Q3 2026 Results: Net Income $3.16M, Up 39.7% YoY

InfuSystem Holdings, Inc. reported net revenues of $37.6 million for the third quarter of 2026, a 3% increase year-over-year, with net income rising to $3.2 million compared to $2.3 million in the prior year period. The company demonstrated improved operational efficiency with operating income growing 24.5% to $4.7 million, supported by a reduction in cost of revenues and strong gross profit margins.

Key figure
Net income $3.16M · +39.7% YoY
6:32 AM ET 8-K
Financial Results

InfuSystem Holdings Financial Results

InfuSystem Holdings reported Q3 2026 net revenues of $37.6 million, a 3% increase year-over-year, driven by strong growth in Oncology and Wound Care. Net income rose to $3.2 million, or $0.15 per diluted share, while Adjusted EBITDA margin expanded to 24.9%. The company reaffirmed its full-year 2026 guidance, expecting pro-forma revenue growth of 6% to 8%.

Term
Q3 2026

“We delivered another strong quarter, achieving record revenue of $37.6 million. After adjusting for the impact of the previously announced GE Healthcare contract restructuring, pro-forma revenue increased 10.2% compared to the prior-year period. Pro-forma growth has accelerated each quarter this year, up from 1.7% in the first quarter and 7.5% in the second quarter. We also increased Adjusted EBITDA by 12.5% and expanded Adjusted EBITDA margin to 24.9% from 22.8% in the prior-year period. These results reflect continued execution of our profitable growth strategy across our diversified operating platform.”

Carrie Lachance, Chief Executive Officer

“Growth during the quarter was driven by Oncology, where revenue grew 7.2%, and exceptional performance in Wound Care. Wound Care revenue increased $2.0 million, or 112%, compared to the prior-year period, including approximately $1.6 million of growth from our compression therapy product lines focused on lymphedema treatment.”

Carrie Lachance, Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.